{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:17:49Z","timestamp":1784204269478,"version":"3.55.0"},"reference-count":23,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.1248\/bpb.b25-00219","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T22:09:30Z","timestamp":1756678170000},"page":"1319-1324","source":"Crossref","is-referenced-by-count":2,"title":["Potential Prognostic Markers for Glioblastoma Associated with the Glioma Immune Microenvironment"],"prefix":"10.1248","volume":"48","author":[{"given":"Kazuya","family":"Tokumura","sequence":"first","affiliation":[{"name":"Department of Bioactive Molecules, Pharmacology, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Hinoi","sequence":"additional","affiliation":[{"name":"Department of Bioactive Molecules, Pharmacology, Gifu Pharmaceutical University"},{"name":"United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University"},{"name":"Center for One Medicine Innovative Translational Research (COMIT), Division of Innovative Modality Development, Gifu University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: a summary. <i>Neuro Oncol.<\/i>, <b>23<\/b>, 1231\u20131251 (2021).","DOI":"10.1093\/neuonc\/noab106"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Behnan J, Finocchiaro G, Hanna G. The landscape of the mesenchymal signature in brain tumours. <i>Brain<\/i>, <b>142<\/b>, 847\u2013866 (2019).","DOI":"10.1093\/brain\/awz044"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Melhem JM, Detsky J, Lim-Fat MJ, Perry JR. Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics<\/i>, <b>19<\/b>, 1705\u20131723 (2022).","DOI":"10.1007\/s13311-022-01251-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) van Solinge TS, Nieland L, Chiocca EA, Broekman MLD. Advances in local therapy for glioblastoma\u2014taking the fight to the tumour. <i>Nat. Rev. Neurol.<\/i>, <b>18<\/b>, 221\u2013236 (2022).","DOI":"10.1038\/s41582-022-00621-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sarantopoulos A, Ene C, Aquilanti E. Therapeutic approaches to modulate the immune microenvironment in gliomas. <i>NPJ Precis. Oncol.<\/i>, <b>8<\/b>, 241 (2024).","DOI":"10.1038\/s41698-024-00717-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jayaram MA, Phillips JJ. Role of the microenvironment in glioma pathogenesis. <i>Annu. Rev. Pathol.<\/i>, <b>19<\/b>, 181\u2013201 (2024).","DOI":"10.1146\/annurev-pathmechdis-051122-110348"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. <i>Cell. Mol. Immunol.<\/i>, <b>21<\/b>, 1354\u20131375 (2024).","DOI":"10.1038\/s41423-024-01226-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tokumura K, Sadamori K, Yoshimoto M, Tomizawa A, Tanaka Y, Fukasawa K, Hinoi E. The bioinformatics identification of potential protein glycosylation genes associated with a glioma stem cell signature. <i>BioMedInformatics<\/i>, <b>4<\/b>, 75\u201388 (2024).","DOI":"10.3390\/biomedinformatics4010005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Fukasawa K, Lyu J, Kubo T, Tanaka Y, Suzuki A, Horie T, Tomizawa A, Osumi R, Iwahashi S, Tokumura K, Murata M, Kobayashi M, Todo T, Hirao A, Hinoi E. MEK5-ERK5 axis promotes self-renewal and tumorigenicity of glioma stem cells. <i>Cancer Res. Commun.<\/i>, <b>3<\/b>, 148\u2013159 (2023).","DOI":"10.1158\/2767-9764.CRC-22-0243"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sasaki Y, Tokumura K, Yoshimoto M, Hinoi E. Association between fat-soluble vitamin metabolic process and glioma progression. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 1682\u20131689 (2024).","DOI":"10.1248\/bpb.b24-00275"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Xiao Y, Wang Z, Zhao M, Deng Y, Yang M, Su G, Yang K, Qian C, Hu X, Liu Y, Geng L, Xiao Y, Zou Y, Tang X, Liu H, Xiao H, Fan R. Single-cell transcriptomics revealed subtype-specific tumor immune microenvironments in human glioblastomas. <i>Front. Immunol.<\/i>, <b>13<\/b>, 914236 (2022).","DOI":"10.3389\/fimmu.2022.914236"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lv X, Wang B, Liu K, Li MJ, Yi X, Wu X. Decoding heterogeneous and coordinated tissue architecture in glioblastoma using spatial transcriptomics. <i>iScience<\/i>, <b>27<\/b>, 110064 (2024).","DOI":"10.1016\/j.isci.2024.110064"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sturm G, Finotello F, List M. Immunedeconv: an r package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. <i>Methods Mol. Biol.<\/i>, <b>2120<\/b>, 223\u2013232 (2020).","DOI":"10.1007\/978-1-0716-0327-7_16"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Osumi R, Sugihara K, Yoshimoto M, Tokumura K, Tanaka Y, Hinoi E. Role of proteoglycan synthesis genes in osteosarcoma stem cells. <i>Front. Oncol.<\/i>, <b>14<\/b>, 1325794 (2024).","DOI":"10.3389\/fonc.2024.1325794"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yoshimoto M, Sadamori K, Tokumura K, Tanaka Y, Fukasawa K, Hinoi E. Bioinformatic analysis reveals potential relationship between chondrocyte senescence and protein glycosylation in osteoarthritis pathogenesis. <i>Front. Endocrinol<\/i>. (Lausanne), <b>14<\/b>, 1153689 (2023).","DOI":"10.3389\/fendo.2023.1153689"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, Trevi\u00f1o V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RGW. Inferring tumour purity and stromal and immune cell admixture from expression data. <i>Nat. Commun.<\/i>, <b>4<\/b>, 2612 (2013).","DOI":"10.1038\/ncomms3612"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jim\u00e9nez-S\u00e1nchez A, Cast O, Miller ML. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. <i>Cancer Res.<\/i>, <b>79<\/b>, 6238\u20136246 (2019).","DOI":"10.1158\/0008-5472.CAN-18-3560"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hennet T. Collagen glycosylation. <i>Curr. Opin. Struct. Biol.<\/i>, <b>56<\/b>, 131\u2013138 (2019).","DOI":"10.1016\/j.sbi.2019.01.015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Liu S, Yu Y, Wang Y, Zhu B, Han B. COLGALT1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of ceRNA networks. <i>Eur. J. Med. Res.<\/i>, <b>27<\/b>, 122 (2022).","DOI":"10.1186\/s40001-022-00745-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kozole SL, Beningo KA. Myosin Light Chains in the Progression of Cancer. <i>Cells<\/i>, <b>13<\/b>, 2081 (2024).","DOI":"10.3390\/cells13242081"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ma J, Cai W, Zhang Y, Huang C, Zhang H, Liu J, Tang K, Xu P, Katirai F, Zhang J, He W, Ye D, Shen GX, Huang B. Innate immune cell-derived microparticles facilitate hepatocarcinoma metastasis by transferring integrin \u03b1(M)\u03b2<sub>2<\/sub> to tumor cells. <i>J. Immunol.<\/i>, <b>191<\/b>, 3453\u20133461 (2013).","DOI":"10.4049\/jimmunol.1300171"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Xu H, Zhang A, Han X, Li Y, Zhang Z, Song L, Wang W, Lou M. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. <i>Cancer Immunol. Immunother.<\/i>, <b>71<\/b>, 645\u2013660 (2022).","DOI":"10.1007\/s00262-021-03022-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Desai I, Thakur S, Pagariya P. Current advances in immunotherapy for cancer. <i>Oral Oncol. Rep.<\/i>, <b>12<\/b>, 100652 (2024).","DOI":"10.1016\/j.oor.2024.100652"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00219\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:51:57Z","timestamp":1757130717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00219\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00219","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"b25-00219"}}